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Abstract
Chagas’ disease is a major public health problem affecting nearly 10 million in Latin America. Despite several experimental
vaccines have shown to be immunogenic and protective in mouse models, there is not a current vaccine being licensed for
humans or in clinical trial against T. cruzi infection. Towards this goal, we used the backbone of Yellow Fever (YF) 17D virus,
one of the most effective and well-established human vaccines, to express an immunogenic fragment derived from T. cruzi
Amastigote Surface Protein 2 (ASP-2). The cDNA sequence of an ASP-2 fragment was inserted between E and NS1 genes of
YF 17D virus through the construction of a recombinant heterologous cassette. The replication ability and genetic stability
of recombinant YF virus (YF17D/ENS1/Tc) was confirmed for at least six passages in Vero cells. Immunogenicity studies
showed that YF17D/ENS1/Tc virus elicited neutralizing antibodies and gamma interferon (IFN-c) producing-cells against the
YF virus. Also, it was able to prime a CD8+ T cell directed against the transgenic T. cruzi epitope (TEWETGQI) which expanded
significantly as measured by T cell-specific production of IFN-c before and after T. cruzi challenge. However, most important
for the purposes of vaccine development was the fact that a more efficient protective response could be seen in mice
challenged after vaccination with the YF viral formulation consisting of YF17D/ENS1/Tc and a YF17D recombinant virus
expressing the TEWETGQI epitope at the NS2B-3 junction. The superior protective immunity observed might be due to an
earlier priming of epitope-specific IFN-c-producing T CD8+ cells induced by vaccination with this viral formulation. Our
results suggest that the use of viral formulations consisting of a mixture of recombinant YF 17D viruses may be a promising
strategy to elicit protective immune responses against pathogens, in general.
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Introduction
Chagas’ disease, caused by Trypanosoma cruzi is considered
a neglected infectious disease, with an estimated 7 to 10 million
cases in Latin America and about 10,000 to 14,000 deaths
annually {Bonaldo, 2000, The yellow fever 17D vaccine virus as
a vector for the expression of foreign proteins: development of new
live flavivirus vaccines.}. The current state of globalization of
Chagas’ disease due to high immigration to non-endemic countries
and also the high economic impact in lost productivity, has
highlighted this emerging disease as a major public health
challenge. This scenario has increased government efforts in
trying to prevent the spread of T. cruzi and still has encouraged
advances in the treatment of the disease and development of
preventive and therapeutic vaccines. Many recombinant proteins,
DNA, viral vectors and heterologous prime-boost regimens of
vaccination suggest that it is feasible to control T. cruzi infection by
vaccination (reviewed by ). Despite these promising results not
a single candidate vaccine has been tested in humans. This is still
an intense field of investigation and could bring economic benefits.
It has been a consensus that a Th1 response with the stimulation
of CD8+ T cell controls T. cruzi infection in murine models and
reduces the severity of the disease in humans. The production of
pro-inflammatory cytokines such as gamma-interferon (IFN-c) and
tumor necrosis factor-alpha (TNF-a) by CD8+ T cells is essential to
a protective response against T. cruzi given that they stimulate the
production of nitric oxide (NO) by macrophages which is directly
involved in the reduction of T. cruzi parasitemia and in vitro
parasite killing. In addition, it was previously shown that a delay in
the CD8+ T cells expansion (and IFN-c production) after a T. cruzi
challenge may be an efficient mechanism to launch the parasite
infection in naı¨ve mice.
Different strategies have been employed in the search of an
effective vaccine against T. cruzi, including genetically attenuated
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parasites, recombinant proteins, viral vectors and DNA vaccines.
Thus, many antigens of T. cruzi as the trans-sialidases (TS), one of
the largest protein families of the parasite, cruzipain, paraflagellar
rod protein-2, GP82, trypomastigotes excretory-secretory antigens
or kinetoplastid protein KMP11 has been the focus of vaccine
development. Among them, the amastigote surface protein (ASP-
2) has displayed enhanced antigenicity in several vaccine
experimental models.
Previous studies have shown that immunization with recombi-
nant proteins or genes based on the amastigote surface protein-2
(ASP-2), as well as heterologous prime-boost, using DNA and
recombinant viral vectors expressing ASP-2 antigens conferred
encouraging protective immunity against T. cruzi. These and other
studies provided evidence that CD8+ and CD4+ Th1 cells are
particularly important to the development of acquired immunity
against experimental infection in mice. These data were obtained
in a T. cruzi highly susceptible mouse strain (A/J) that totally
succumb with a relatively small dose of the Y strain of the T. cruzi
parasite after a short period of time (less than 30 days after
infection).
The Yellow Fever vaccine virus (YF 17D) is a well-established
human vaccine that has proven to set off a polyvalent innate
immune response resulting in life-long immunity that includes
a robust neutralizing antibody response that may persist for up to
40 years after vaccination, a mixed CD4+ T helper (Th1 and Th2)
cell profile and a potent cytotoxic CD8+ T cell response. An
important aspect of the YF 17D vaccine is its capacity to induce
specific CD8+ T cells early after vaccination (5 days) in humans or
in mice. Moreover, the production of the soluble mediator IFN-c,
which plays an essential role in YF infection, is also initiated 5 to 7
days after YF vaccination. Therefore we expect that YF 17D virus
could be the vector of choice to elicit the appropriate immune
response since it is well known that a rapid CD8+ T cell induction
(and IFN-c production) are advantageous features against T. cruzi
infection in mice and humans.
Based on these data following vaccination of A/J mouse model,
we attempted to build on this strategy by generating recombinant
YF 17D viruses that express CD4+ and CD8+ T cells epitopes
derived from the ASP-2. We have recently reported the
characterization of two immunogenic recombinant YF 17D
viruses that expressed the immunodominant CD8+ T cell,
TEWETGQI epitope of ASP-2 in the envelope protein (E) and
in the intergenic region of NS2B and NS3 protease. Immunization
of A/J mice with the recombinant YF 17D viruses induced
a TEWETGQI-specific CD8+ T cell response and delayed mouse
mortality after a T. cruzi challenge.
In this work, we approached the expression of a larger fragment
of ASP-2 (ASP-2261–380), inserting it between the E (Envelope) and
the non-structural NS1 protein coding genes of YF 17D virus by
means of a previously established methodology. We studied the
protective immunogenicity of this recombinant ASP-2261–380 YF
17D virus in mice administrating it alone or combined with the YF
17D virus expressing the ASP-2 TEWETGQI epitope between
NS2B and NS3 proteins. In the latter, we would like to verify
whether the simultaneously immunization recombinant YF 17D
viruses, which may present antigens through different cell
compartments (at the endoplasmatic reticulum or in the cytosol,
respectively), and most likely leading to distinct pathways of
immune-presentation, could elicit a more protective immune
response against T. cruzi. In this regard, our results demonstrate for
the first time that the co-administration of recombinant yellow
fever viruses can elicit enhanced protection of the animals against
T. cruzi challenge with decrease in the rates of mortality and
parasitemia representing thus a promising strategy to develop
a vaccine for Chagas’ disease.
Materials and Methods
Mice and Parasites
Female 4 to 6 week-old A/J mice in this study were obtained
from CECAL, Fiocruz (Rio de Janeiro, Brazil) or purchased from
CEMIB/UNICAMP. This study was carried out in strict
accordance with the recommendations in the Guide for the
National Council for Control of Animal Experimentation (CON-
CEA). The protocol was approved by the Committee on the Ethics
of Animal Experiments (CEUA) of Oswaldo Cruz Foundation
(Permit Number: L-0032). Accordingly, all surgery was performed
under anesthesia, and all efforts were made to minimize suffering.
Animals were twice monitored daily (morning and evening) by
a technician responsible for evaluating the appearance of clinical
signs such as changes in behavior (low activity, abnormal
locomotion, unusual aggressiveness and continuous licking of
body parts), piloerection or frequency of feeding (decreasing of
food or water consumption). Occurrence of some of these
symptoms were evaluated as signs of animal distress and suffering
and were critical to the ultimate decision of euthanasia for humane
reasons. Mice were human sacrificed by intraperitoneal injection
of sodium thiopental (200 mg/kg). After allowing sufficient time
for the animal to lose consciousness, we performed exsanguination
and spleen collection of each animal.
Bloodstream trypomastigote forms of T. cruzi, Y strain, were
obtained from T. cruzi-infected Swiss mice at the peak of the
parasitemia. Briefly, male mice (18–20 g) were inoculated in-
traperitoneally with 36105 trypomastigotes. Total blood sample
was harvested by heart puncture after 7 days post-infection and
the parasites were purified by differential centrifugation.
Cell Culture and Vaccine Virus
Vero cells (ATCC) were grown in Earle’s 199 medium
supplemented with 5% fetal bovine serum (FBS). As a vaccine
control virus, we have utilized the YF sub-strain 17DD (Bio-
Manguinhos, Rio de Janeiro, Brazil).
Virus Recovery, Biological and Genetic Studies
The recombinant ASP-2261–380 cassette was constructed by
amplification of ASP-2 gene cloned in the plasmid pIgSPclone9
(GenBank: AY186572.1. The strategy of the heterologous cassete
construction was based on the approach previously described.
Initially, the ASP-2261–380 fragment of 406 bp was amplified with
the positive primer corresponding to 27 nucleotides of the NS1
gene and 20 nucleotides from ASP-2261–380 and the negative
primer corresponding to the last 27 nucleotides of the ASP-2261–
380 gene plus the initial 27 nucleotides coding for the amino-
terminal domain of the DEN4 E protein stem-anchor region. The
second fragment (336 bp) was based on the amplification of the YF
cDNA plasmid and was made of 21 nucleotides from the carboxi-
terminal of the ASP-2261–380 gene followed by the DEN4 stem-
anchor region (288 bp) and 27 nucleotides from the amino-
terminus of the NS1 gene. Both fragments were mixed in
equimolar amounts and reamplified with terminal cassete primers.
The resulting fragment of 708 bp was purified with silica-based kit
(QIAGEN) and cloned in the pCR-Blunt II TOPO plasmid
(Invitrogen) using chemically competent E. coli DH5-a. The insert
was removed by digestion with Nar I and Eag I and ligated into YF
pT3 plasmid. The insertion and its orientation was verified by
nucleotide sequencing.
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To recover the recombinant YF17D/ENS1/Tc virus we have
employed the two infectious-plasmid clone technology, as pre-
viously described. After the transfection of viral RNA into Vero
cells and the onset of cytopathic effect, the viral supernatant was
collected and used to re-infect Vero cell monolayers, generating
a second passage viral stock for all subsequent experiments.
Viral proliferation curves were determined by infecting mono-
layers of Vero cells at MOI of 0.02. Cells were seeded at a density
of 62,500 cell/cm2 and infected 24 hs later. Samples of the cell
culture supernatant were collected at 24-hour intervals post-
infection. Viral yields were estimated by plaque titration on Vero
cells. The different viral growth peaks were compared using the
Mann-Whitney test. (GraphPad Prism 5.03 Program). The
differences were only considered significant when P,0.05.
To access the integrity of the heterologous ASP-2 insert, viral
RNA samples were obtained and used as a template for cDNA
synthesis as previously described. Amplification of the viral
genomic E-NS1 region encompassing the heterologous insert
was performed using an antisense (YF genome position 2619–
2639) and sense primer (genome position 1639–1659). PCR
products were submitted to nucleotide sequencing as described
elsewhere. In the genetic stability studies, recombinant viruses
were submitted to two independent series of six passages in Vero
cells at MOI of 0.02. In the second and the sixth passage, viral
RNA was extracted at 72 hs post-infection and submitted to RT/
PCR and nucleotidic sequencing.
Detection of YF and T.cruzi Antigens in Vero Cells by
Immunofluorescence Studies
To detect the expression of YF and ASP-2 antigens in YF virus
infected Vero cells immunofluorescence analysis was employed as
previously described. As primary antibodies, mouse anti-TE-
WETGQI or mouse hyperimmune ascitic fluid to YF 17D
(ATCC) were used. As secondary antibodies, we used Alexa Fluor
546 goat anti-mouse IgG-Invitrogen or Alexa Fluor 488 goat anti-
mouse IgG-Invitrogen, according to the manufacturer’s recomen-
dations. To determine the reactivity to T.cruzi amastigotes of sera
from vaccinated mouse groups to T. cruzi amastigotes, Vero cells
were infected during 24 hours with 106 T. cruzi trypomastigotes (Y
strain) in a 10:1 (parasite/cell) rate. After this time, parasites were
removed with PBS washing and infected-Vero cells were in-
cubated for an additional period of 72 hours. Cell monolayer was
fixed and washed with PBS containing 0.5% of Triton X-100 and
permeabilized followed by incubation with PBS 4% BSA. T. cruzi
amastigotes infected-cells were then incubated with sera of mice
immunized with YF17/ENS1/Tc. Secondary fluorescein isothio-
cyanate (FITC)-conjugated anti-mouse antibodies were used. Both
preparations were treated with SlowFade-Gold antifade reagent
with DAPI (Invitrogen) and analysed by Fluorescence Microscopy
with an Olympus IX51 Inverted Microscope.
Mouse Assays
The ability of the recombinant YF viruses to elicit neutralizing
antibodies directed against YF virus was evaluated by immunizing
groups of 4 to 6 week old A/J mice subcutaneously with two doses
of 100,000 PFU of either YF 17DD vaccine, YF17D/NS2B3/Tc,
YF17D/ENS1/Tc or YF 17D Formulation 1 with an interval of
15 days. Two weeks after the last immunization, mice were bled
and individual serum samples were treated 56uC for 20 minutes.
YF neutralizing antibody titer was determined by plaque reduction
neutralization test (PRNT50). Titers were calculated as the highest
dilution of antibody reducing 50% of the input virus plaques.
Kruskall-Wallis test was used to compare the mean titers of
neutralizing antibodies of the experimental groups.
To perform T. cruzi challenge assays, groups of five 4–6 week-
old A/J mice were immunized with the different viruses as
described above. Four weeks after the last dose, mice were
challenged intraperitoneally with 250 bloodstream trypomastigotes
of the T. cruzi Y strain. After challenge, clinical symptoms and
deaths were daily recorded for a period of 60 days. Results
represent pooled data from two independent experiments in-
volving five to six animals per group and per experiment (except
for YF17D/ENS1/Tc followed by YF17D/NS2B3/Tc, in the
homologous prime-boost). Survival curves (Kaplan-Meyer meth-
od) were compared across groups and formally tested using the
logrank test. Average survival times (AST) were compared
between groups and tested by Mann Whitney test (GraphPad
Prism 5.03 Program).
Parasitemia curves were determined by collecting blood from
the tail vein daily after T. cruzi challenge and the level of
parasitemia was calculated by Pizzi-Brener method. Results of
parasitemia are representative of two independent experiments
involving four to five animals per group. The values of peak
parasitemia of each individual mouse were log transformed before
being compared by one-way analysis of variance followed by
Tukeys test.
To establish whether the T. cruzi recombinant YF viruses could
induce IFN-c, groups of A/J mice were immunized as described
above. One week after the first or the second dose, and two weeks
after T. cruzi challenge, mice were sacrificed and the spleens
removed. The IFN-c ELISPOT assays were carried out using BD
IFN-g ELISPOT set (BD – Biosciences Pharmingen, San Diego-
CA). All ELISPOT assays were done as previously described.
Spleen cells were incubated with medium alone, 10 mg/mL of
synthetic TEWETGQI peptide (Invitrogen), 10,000 PFU/mL of
inactivated YF 17DD virus or 4 mg of concanavalin A (Sigma)
diluted in RPMI 10% FBS medium. Spots were counted with an
Immunospot reader (Cellular Technology Ltd., Cleveland, OH)
using the Immunospot Software version 3 by the ELISPOT
Platform of PDTIS/Fiocruz - Rio de Janeiro. Statistical signifi-
cance of the differences among immunization groups was verified
by ANOVA Tukeys test. Data are representative of two or more
independent experiments.
Results
Design and Characterization of Recombinant 17D Viruses
Expressing T. cruzi ASP-2261–380
The ASP-2 261–380 fragment derived from Y strain of T. cruzi
(Figure 1A) [35,37] was cloned into the intergenic E and NS1
region of the YF 17D genome [41] (Figure 1B), by means of the
duplication of functional signalase cleavage motif as well as of
conserved amino acid sequences flanking this region [41]. This
structural arrangement allows the correct processing by cell signal
peptidases in the ER membrane of the viral E and NS1 proteins as
well as the recombinant ASP-2 protein with reduced disturbance
in the virus replication cycle. The recombinant ASP-2261–380
cassette was predicted to be composed of 227 amino acids with an
expected molecular weight of 24.7 kDa. The recombinant protein
fragment ASP-2 contains two transmembrane helix domains
corresponding to the transmembrane motifs present in the
carboxi-terminus Den 4 E protein anchor region (TM1 and
TM2). We could hypothetically corroborate the existence of these
domains in the recombinant cassette by analysing the recombinant
ASP-2 protein sequence with the TMHMM program for the
prediction of transmembrane helices in proteins. Hence, the
presence of these two transmembrane motifs in the recombinant
cassete should promote the anchoring of the heterologous protein
T. cruzi ASP-2 Recombinant YF Virus Vaccination
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in the luminal side of the ER membrane, as we could demonstrate
elsewhere. In this work, it was utilized a formerly described T. cruzi
recombinant virus, denominated YF17D/NS2B3/Tc. This virus
expresses the immunodominant ASP-2320–327 TEWETGQI epi-
tope.
The recombinant YF/ASP-2261–380 virus, identified as YF17D/
ENS1/Tc was evaluated in terms of the replicative capability in
comparison to the YF vaccine virus (substrain 17DD) and the
other recombinant YF17D/NS2B3/Tc virus. The proliferation
rate of the recombinant virus was lower than the vaccine
counterpart (Figure 1C). The maximum virus yields occurred at
72 h post-infection with YF 17DD virus exhibiting a titer of
7.5660.07 log10PFU/mL while the recombinant YF17D/ENS1/
Tc virus peaked at 96 h with a titer of 6.7660.35 log10PFU/mL.
However, at these peak time points the differences between
YF17D/ENS1/Tc and the control virus were not statistically
significant (P value = 0.1). We observed a reduced plaque size of
the recombinant virus YF 17D/ENS1/Tc as compared to the
Figure 1. Characterization of recombinant YF 17D virus expressing Trypanosoma cruzi ASP-2261–380 fragment. A) Schematic
representation of the ASP-2 protein (Y strain clone 9) presenting the ASP box motifs, the highly conserved VTVxNVxLYNR sequence and the
immunogenic fragment comprising amino acids 261 to 380, which includes the CD8+ T cell TEWETGQI epitope (modified from and ). B) Diagram
showing the corresponding insertion site of ASP-2261–380 in the YF genome between E and NS1 genes (indicated by the star). The YF virus genome is
translated in a precursor polyprotein which is proteolytically processed by the viral protease complex NS2B NS3 (open arrows), the host signalase
(dark arrows), furin (open triangle) and unknown host protease (dark triangle). C) Replication curve in Vero cells of YF17D/ENS1/Tc (full squares),
YF17D/NS2B3/Tc (full circles) and YF 17DD (empty circles). Each curve point represents average titer and standard deviation obtained from three
different experiments. D) RT-PCR fragments obtained from YF 17DD viral RNA (lane 1); or recombinant YF17D/ENS1/Tc viral RNA collected from the
second passage (lane 2) and sixth passage (lane 3). MW (bp), Low Mass DNA Ladder.
doi:10.1371/journal.pone.0059347.g001
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control vaccine YF 17DD virus (data not shown). We also
compared the replication efficacy of the YF17D/ENS1/Tc but no
statistically significant differences between them were seen despite
that YF17D/NS2B3/Tc peaked earlier (at 72 h), similarly to YF
17DD virus, than the YF17D/ENS1/Tc virus (at 96 h).
We also assessed the genetic stability of the YF17D/ENS1/Tc
virus bearing the ASP-2261–380 gene, since the genetic stability is
a concern for the development of vaccine viral vectors. In this
regard, we carried out two series of separate serial passages in
Vero cells per virus sample, infecting cells with a MOI of 0.02. At
the second (2P) and sixth passage (6P), we performed RT-PCR
and nucleotide sequencing analysis of amplicons containing the E/
NS1 insertion region of the recombinant YF genome. In RT-PCR
analysis, a DNA amplicon band of about 1,700 bp in size indicates
the integrity of cassete region (Figure 1D, lanes 2 and 3). On the
other hand, a DNA amplicon of 1,000 bp was obtained for the
control virus YF 17DD, which contains no heterologous cassete
(Figure 1D, lane 1). In conclusion, the integrity of the heterologous
cassete was confirmed up to the sixth serial passage of YF17D/
ENS1/Tc virus in Vero cells. Furthermore, we plaqued the
recombinant virus belonging to the second and the sixth passages
and no variation in plaque size was observed (data not shown).
Detection of YF Virus and T. cruzi Antigens
To confirm the expression of the heterologous T. cruzi ASP-
2261–380 cassette by the recombinant YF17D/ENS1/Tc virus in
infected Vero cells, we performed an indirect immunofluorescence
assay using antibodies specific to TEWETGQI epitope (320 to 327
amino acids of ASP-2) or directed to YF antigens. The YF antigens
were equally detected in Vero cells infected with vaccine 17D and
the recombinant YF17D/ENS1/Tc and YF17D/NS2B3/Tc
viruses (Figure 2A and B), whereas TEWETGQI epitope was
specifically detected in the YF 17D/ENS1/Tc and YF17D/
NS2B3/Tc virus infected cells (Figure 2D). Interestingly, the
labeling pattern of YF 17D/ENS1/Tc in infected Vero cells was
mainly localized in the perinuclear region suggesting that the
heterologous recombinant protein is associated with the ER
compartment, as previously observed for the Green Fluorescent
Protein (GFP) using the same approach.
Recombinant YF Virus Immunization Induces Antibodies
to T.cruzi Amastigotes
Aiming to better characterize the YF17D/ENS1/Tc and
YF17D/NS2B3/Tc viruses, we also performed immunofluores-
cence assays using sera from immunized A/J mice. We would like
to establish if the vaccination with the recombinant viruses could
elicit antibodies to the intracellular amastigote forms of T. cruzi in
infected Vero cells. Remarkably, both viruses were able to induce
antibodies against ASP-2 antigens, which could bind the ASP-2 on
the amastigote cell surface in T. cruzi infected Vero cells (Figure 3A
and B). A similar recognition profile could be obtained using
control animal sera which received the TEWETGQI peptide
emulsified with Freunds Adjuvant (data not shown). Therefore, the
immunization with the recombinant YF17D/ENS1/Tc and
YF17D/NS2B3/Tc viruses could induce ASP-2 antibodies that
are reactive to this protein in the context of the amastigote surface.
Protective Immune Response Against T. cruzi
To approach the use of these recombinant YF viruses as T. cruzi
vaccine candidates, we immunizated A/J mice with them and
challenged the animals with a lethal dose of T. cruzi trypomasti-
gotes four weeks after from the last vaccine dose. The animal
groups which were received either YF17D/NS2B3/Tc or
YF17D/ENS1/Tc virus showed a reduction in mouse mortality
of 16% and 25% at 30 dpi, respectively, while all the animals of
the control group YF 17DD or Mock (data not shown) died
(Figure 4A). Additionally, we could also observe an increment in
the average survival time (AST) of these experimental groups: 26
days for mice vaccinated with YF17D/ENS1/Tc virus and of 27
days for those which received YF17D/NS2B3/Tc virus. In
contrast, animals from the YF 17DD or Mock group displayed
a significantly lower value of AST (20 days and 21 days,
respectively; P,0,0001, Mann Whitney test). However, these
scores were not sustained after 60 dpi. Only 16% and 8% of A/J
mice, which were immunized with recombinant ASP-2 261–380 or
TEWETGQI virus, respectively, remained alive (Figure 4A).
Notwithstanding the low protection afforded by YF17D/ENS1/
Tc or YF17D/NS2B3/Tc virus vaccination, we decided to test
a mixture of these YF 17D recombinant viruses in mouse
immunization. We wonder if a viral formulation could enhance
the immunogenicity of viruses in A/J mice, perhaps promoting
a more balanced MHC class I and II-restricted presentation and
consequently to an improved immune-protective response. Using
this rational, two different 17D viral compositions were utilized,
Formulation 1 (composed of 50% of YF17D/NS2B3/Tc and 50%
of YF17D/ENS1/Tc virus) and Formulation 2 (composed of 75%
of YF17D/ENS1/Tc and 25% of YF17D/NS2B3/Tc). Notably,
groups of animal vaccinated with YF 17D viral formulations
exhibited a higher percentage of survivors after the lethal T. cruzi
challenge. Formulation 1 protected 58% of mice at 60 dpi, with an
AST of 29 days (Figure 4A) while Formulation 2 protected 43% of
mice at 60 dpi, with an AST of 24 days (data not shown). This
enhancement of the AST was statistically significant in comparison
for the group vaccinated with YF 17DD (P,0.01).
To determine if a heterologous prime-boost vaccination
sequentially using the recombinant viruses could lead to the same
degree of protection provided by the formulations, we first
vaccinated mice with the YF17D/ENS1/Tc virus (first dose)
and subsequently, with the YF17D/NS2B3/Tc virus (second
dose). We verified that only 9% of A/J mice vaccinated with the
prime-boost regimen was protected against the lethal T. cruzi
challenge at 60 dpi (data not shown). Therefore, the sequencial
immunization strategy (heterologous prime-boost) was not able to
elicit the same level of protection as the co-administration of both
recombinant viruses (viral formulation).
We also analysed the parasitemia in challenged animals that
were previously immunized with Formulation 1, since it could
display the most favourable degree of protection regarding the
Formulation 2 and the homologous prime-boost regimen. So, we
chose it to study the T. cruzi parasitemia comparing to the two
vaccines composed by only a single recombinant virus. Corrob-
orating the effect on the decrease of mortality and the increase of
AST, mice vaccinated with Formulation 1 presented a lower
parasitemia (average of 1206104 parasites/mL) than the animals
vaccinated with YF 17DD (4106104 parasites/mL) or YF17D/
NS2B3/Tc (3606104 parasites/mL) (P,0.05) (Figure 4B). How-
ever, no significant difference was observed when we compared
the peak parasitemias of mice immunized with YF17D/ENS1/Tc
(1856104 parasites/mL) or Formulation 1 (1206104 parasites/
mL). The individual mouse values per immunizing group are
shown in Figure 4C to F.
Production of Neutralizing Antibodies to Yellow Fever
Virus
One important point to be considered in the efficacy of
recombinant YF vaccines is the ability to elicit neutralizing
antibodies to YF virus. So, we decided to compare the ability of
T. cruzi ASP-2 Recombinant YF Virus Vaccination
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these different immunization regimens to induce this kind of
immune response against YF virus. Remarkably, when we
compared the distinct recombinant YF groups to the control
vaccine 17DD virus, there was a general decrease in titers of
neutralizing antibodies found in mouse groups vaccinated with any
recombinant virus vaccine. Thus, in YF 17D/ENS1/Tc virus
vaccinated group, despite the seroconversion rate of 100%, the
titers of neutralizing antibodies to YF were significantly lower
when compared to the YF 17DD group, displaying titers ranging
from 1:18 to 1:235; with an average titer (GMT) of 1:69, while the
vaccine control group ranged from 1:99 to more than 1:1,280;
with a GMT of 1:559 (Table 1). This difference in YF neutralizing
antibody production was statistically significant (P,0.0001)
suggesting that the YF 17D/ENS1/Tc virus might be more
attenuated in vivo.
Despite the fact that the virus formulation seemed to be more
immunogenic in challenge experiments, it caused a partial
seroconversion ratio of immunized A/J mice and was not able
to induce similar antibody titers as the vaccine YF 17D virus was
(Table 1). The titers obtained for Formulation 1 ranged from 1:18
to 1:86 and displayed a GMT of 1:51 while for Formulation 2 it
varied from 1:10 to 1:82 with a GMT of 1:37. There was no
significant difference between them. In contrast, antibody titers
induced by TEWETGQI expressing virus, YF 17D/NS2B3/Tc,
were significantly higher than both viral formulations (P,0.05)
and did not exhibit difference to the titer found in the YF 17DD
control group.
Vaccination with YF Virus Formulation Induces IFN-c
Mediated-cellular Immune Responses
To better characterize the protection promoted by YF 17D
Formulation 1 immunization, we collected the spleens from the
animals one week after the first and the second dose of vaccination
and determined the amount of IFN-c-secreting splenocytes upon
stimulation with T. cruzi T CD8+ TEWETGQI epitope or
inactivated YF 17DD virus.
Seven days after the first vaccine dose, we observed that all
immunization groups, i.e., single recombinant virus vaccines,
Formulation 1 and YF 17DD vaccine control were not able to
induce a considerable response of IFN-c spot forming-cells (SFC)
specific to yellow fever since there were no statistically differences
among the number of IFN-c secreting splenocytes between
vaccinated groups and the mock group (Figure 5A). However,
after the second dose, the numbers of IFN-c-secreting splenocytes
significantly increased for all immunized mouse groups compared
to the negative control group (P,0.05). Noteworthy, the YF
vaccinated groups did not exhibit any difference in the amount of
IFN-c-secreting splenocytes after the second dose (159 SFC/106
cells for YF 17DD, 149 SFC/106 cells for YF 17D/NS2B3/Tc,
215 SFC/106 cells for YF 17D/ENS1/Tc and 151 SFC/106 cells
for Formulation 1; Figure 5B). Therefore, the cellular responses
observed for all groups indicated an equivalent capacity for
eliciting and expanding specific T cells against the YF virus
antigens (Figure 5B).
In the next study, we investigated the ability of the recombinant
T.cruzi YF viruses to elicit IFN-c-producing cells specific to the
immunodominant H-2Kk - TEWETGQI epitope of ASP-2 in A/J
mice before and after T. cruzi trypomastigote challenge. In-
terestingly, after a single dose, we detected a significantly higher
number of SFCs in mice immunized with Formulation 1 (95 SFC/
106 cells) in comparison to YF 17DD (1 SFC/106 cells), Mock
(4 SFC/106 cells) or YF 17D/ENS1/Tc (37 SFC/106 cells)
(P,0.05; Figure 5C). The YF17D/NS2B3/Tc virus was also
capable to elicit statistically significant T cell response to the T.
Figure 2. Expression of the T. cruzi TEWETGQI epitope by the recombinant YF17D/ENS1/Tc virus. Indirect immunofluorescence assay of
Vero cells infected with YF 17DD vaccine virus (A and D), recombinant YF17D/ENS1/Tc viral (B and E), and recombinant YF17D/NS2B3/Tc virus (C and
F). Cells were stained with a mouse polyclonal hyperimmune serum to YF 17D (panels A, B and C) or a polyclonal antibodies directed to the
TEWETGQI epitope (panels D, E and F). The employed secondary antibodies were labeled with Alexa Fluor 488 (A, B and C) and Alexa Fluor 546 (D, E
and F).
doi:10.1371/journal.pone.0059347.g002
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cruzi antigen after one dose (41 SFC/106 cells) in comparison to
YF 17DD or Mock (P,0.05) although not in the same magnitude
as Formulation 1 (95 SFC/106 cells). After the second dose, we
could observe an overall expansion of the specific TEWETGQI-
peptide IFN-c-producing cells in mice immunized with YF 17D/
NS2B3/Tc, YF 17D/ENS1/Tc, and Formulation 1, reaching
135, 234 and 223 SFC/106 cells, respectively, as compared to the
YF 17DD group which exhibited 6 SFC/106 cells (Figure 5D). All
in all, it is reasonable to consider that the YF 17DD virus as well as
the recombinant T. cruzi YF virus, including the Formulation 1,
displayed a similar ability to induce a IFN-c immune cell response
specific to YF virus after two doses of vaccination, whereas this
kind of immune response specific to the TEWETGQI peptide was
higher for Formulation 1 and YF 17D/ENS1/Tc immunized-
groups in comparison to the YF 17DD, Mock and the YF 17D/
NS2B3/Tc groups. These data show a more divergent aptitude in
eliciting cellular responses specifically directed to the TE-
WETGQI epitope than to the Yellow Fever Virus specific epitopes
(although YF 17D/ENS1/Tc could induce higher TEWETGQI
or YF specific cellular responses than YF17D/NS2B3/Tc virus
after two doses).
After T. cruzi challenge, higher numbers of IFN-c SFC were
achieved in the groups immunized with Formulation 1
(1661 SFC/106 cells) followed by the YF 17D/ENS1/Tc
(1634 SFC/106 cells) and the YF 17D/NS2B3/Tc virus
(1030 SFC/106 cells) in comparison to the YF 17DD group
(94 SFC/106 cells) or Mock (1 SFC/106 cells, P,0.05; Figure 5E).
Therefore, the number of IFN-c producing T cells specific to the
TEWETGQI epitope obtained from the splenocytes of mice
immunized with each of the YF recombinant viruses or in
combination (Formulation 1) was up to six-fold higher after
encountering the parasite antigens suggesting that the recombi-
nant viruses were capable to elicit and considerably expand
specific T cells after a T. cruzi challenge (Figure 5E).
Discussion
Despite considerable efforts over the last decades, the de-
velopment of a Trypanosoma cruzi vaccine remains elusive. The use
Figure 3. Detection of specific antibodies against T. cruzi amastigotes after immunization of mice with YF17D/ENS1/Tc or YF17D/
NS2B3/Tc virus. Panels A and B show T. cruzi-infected Vero cells stained with sera from YF17D/ENS1/Tc virus immunized mice. Panels C and D show
T. cruzi-infected Vero cells stained with sera from YF17D/NS2B3/Tc virus immunized mice. These preparations were also stained with a FITC
conjugated-secondary antiboby (A and C) and DAPI (B and D). Arrows indicate amastigote nests in the cytoplasm of Vero cells. Note the intense
serum antibody reactivity (green) with the intracellular parasites. DAPI stained host cell nucleus and also the nucleus and kinetoplast of the parasites.
Images obtained from Zeiss Axioplan microscope equiped with epifluorescence (objective 63x).
doi:10.1371/journal.pone.0059347.g003
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of viral vectors may be one of the promising strategies to elicit
protective immune responses against this parasite, which may
require the activation of a Th1 immune profile, with the
stimulation of CD8+ T cells. Given the outstanding properties of
the YF 17D virus with regard to the CD8+ T cell response we
consider that YF 17D virus is an appropriate vector to deliver T.
cruzi epitopes and generate the required immune response for an
ideal anti-parasitic vaccine.
Amastigote surface protein 2 is expected to be surface anchored
by glycosylphosphatidylinositol (GPI) structures and may be
released into the host cell cytoplasm throughout the cycle of
intracellular development of the parasite. ASP-2 harbors many
major histocompatibility complex (MHC) class I-restricted epi-
topes shown to be recognized by specific cytotoxic T cells derived
from mice or man. These specific CD8+ T-cells directed to
amastigote forms can lyse T. cruzi infected cells and produce
Figure 4. Trypomastigote-induced mortality and parasitemia in immunized A/J mice. A) mouse survival after T. cruzi challenge. Kaplan-
Meier curves of (7 to 12 mice per group) of experimental groups which were immunized with the recombinant viruses YF17D/NS2B3/Tc (N), YF17D/
ENS1/Tc (.), Formulation 1 (50% of YF17D/ENS1/Tc and 50% of YF17D/NS2B3/Tc viruses) (¤) or vaccine YF 17DD control virus (%). Differences
between the groups immunized with the recombinant 17D viruses and that one which received the YF 17DD vaccine were statistically significant
(***P,0.0001, logrank test). B) Average value of trypomastigote-induced parasitemias of immunized A/J mice and intraperitoneally challenged with
250 bloodstream trypomastigotes. The parasitemia for each individual mouse is represented in the graphs for: (C) mice immunized with YF 17DD; (D)
mice immunized with YF 17D/NS2B3/Tc; (E) mice immunized with YF 17D/ENS1/Tc; (E) immunized with Formulation 1. The parasitemic peak of mice
immunized with Formulation 1 were lower than the parasitemias of mice immunized with YF 17DD or YF17D/NS2B3/Tc (*P,0.05, Tukey’s test).
doi:10.1371/journal.pone.0059347.g004
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important pro-inflammatory cytokines such as IFN-c that may
help to eliminate intracellular parasites. In addition, immunization
with fragments or peptides derived from ASP-2 has been
demonstrated to generate specific type 1 IFN-c producing and
cytotoxic T cells in vaccinated mice. For these reasons, ASP-2 is
considered one of the best targets for an effective host response.
Table 1. Immunogenicity of YF 17D recombinant viruses or viral formulations in A/J mice.
Immunogen Animals (n) Seroconversion (%) PRNT50
*
GMT 6 SD Titer Range
YF 17DD 15 100 $5596410 99–$1280
YF17D/NS2B3/Tc 10 100 $2776465 47–$1280
YF17D/ENS1/Tc 10 100 69676** 18–235
Formulation 1a 10 90 51625** 18–86
Formulation 2b 10 50 37626** #10 – 82
Earle’s Medium 199 10 0 #10 #10
a50% of YF17D/ENS1/Tc and 50% of YF17D/NS2B3/Tc viruses.
b75% of YF17D/ENS1/Tc and 25% of YF17D/NS2B3/Tc viruses.
*values indicate the reciprocal of the dilution yielding 50%. PRNT, Plaque Reduction Neutralization Test; GMT, Geometric Mean Titre.
**differences in the titers of neutralizing antibodies virus between YF 17DD and the recombinant viruses or viral formulations were statistically significant (P value
,0.05; Kruskal-Wallis test).
doi:10.1371/journal.pone.0059347.t001
Figure 5. Induction of IFN-c secreting splenocytes in vaccinated mice before and after T. cruzi challenge. Groups of A/J mice were
immunized once or twice with medium (mock) (#), YF 17DD vaccine (%), YF17D/NS2B3/Tc virus (N) and YF17D/ENS1/Tc virus (.) or alternatively
with Formulation 1 (50,000 PFU of YF17D/NS2B3/Tc and 50,000 PFU of YF17D/ENS1/Tc) (¤) and challenged or not with 250 T. cruzi trypomastigotes.
Spleen cells of each mouse were obtained one week after the first dose (A and C), one week after the second dose (B and D) or two weeks after
challenge (E) and after that, were stimulated in vitro with YF 17DD inactivated virus (A and B) or TEWETGQI-peptide (C, D and E) to assess cellular
responses to YF peptides or to the T. cruzi peptide, respectively. Results represent IFN-c producing cells (SFC) per 106 spleen cells. Asterisks indicate
statistically significant differences between groups of immunization in comparison to Mock (A and B) or in comparison to Mock and YF 17DD group
(C, D and E) and were done by ANOVA Tukeys test (***P,0.0001; **P,0.01; * P,0.05).
doi:10.1371/journal.pone.0059347.g005
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We have previously demonstrated that vaccination of a high
susceptible mice model, A/J, with recombinant YF 17D viruses
expressing an ASP-2 CD8+ T cell epitope, TEWETGQI, induced
specific IFN-c producing-cells but only partial protection of mice
after a T. cruzi challenge. In this study, we have used the previously
described YF virus platform of insertion between the E protein and
the non-structural NS1 protein to express a larger immunogenic
fragment of T. cruzi ASP-2 protein including the TEWETGQI
epitope, resulting in the YF 17D/ENS1/Tc virus. This viral
construct is stable since the integrity of the expression cassette was
maintained until at least the sixth serial passage in Vero cells.
However, this virus exhibited reduced fitness in vivo since it elicited
lower titers of neutralizing antibodies as compared to animals
vaccinated with YF 17DD virus. We are aware that studies to
determine antigenic mass production in viremic animals are
necessary to correlate the over-attenuation of YF 17D/ENS1/Tc
with its lower immunogenicity as measured by neutralizing
antibodies to YF. Nevertheless, it has been shown that even low
detectable levels of YF 17D viremia (less than 18 copies/mL) did
not impair the induction of T cell immune response (up to
388 SFU/106 cells) in vaccinated Indian rhesus macaques.
In our studies in A/J mice, two doses of YF 17D/ENS1/Tc
virus elicited antibodies against amastigote forms of T. cruzi and
induced a significant number of IFN-c producing-T cells directed
to the T. cruzi TEWETGQI peptide. However, there was no
complete protection against a lethal T. cruzi challenge which
contrasts to other studies that described 100% of protection when
mice were vaccinated with the recombinant protein expressing the
same antigens derived from ASP-2 in the presence of CpG ODN
1826 adjuvant. Although the regimens of immunization greatly
contrast, it is possible that administration of this adjuvant, a Toll-
like receptor 9 agonist, is enhancing protective CD8+ T cell
response in those mice. We might also consider that the major
retention of ASP-2261–380 antigens in the ER, as expressed by the
YF17D/ENS1/Tc virus may contribute to a restricted pre-
sentation of antigens derived from this ASP-2 fragment via
MHC class I.
A recent report has shown that the utilization of distinct viral
vectors as a single mixture composition rather than as heterolo-
gous prime-boost regimen is a more promising and effective
vaccine strategy allowing enhanced protection against pre-
erythrocytic malaria in a mouse model. Given the low immuno-
genicity of the YF17D/ENS1/Tc virus, perhaps due to the fact
that the expressed the heterologous ASP-2 antigen by YF 17D/
ENS1/Tc virus is retained into the ER compartment, we
introduced a new immunization strategy to achieve a better
immune response and higher level of protection of A/J mice
against T. cruzi challenge. In this regard, we used YF 17D viral
formulations that consisted of two YF 17D recombinant viruses
(YF17D/ENS1/Tc and YF17D/NS2B3/Tc), to vaccinate A/J
mice. The choice of using YF17D/NS2B3/Tc recombinant virus
simultaneously with YF17D/ENS1/Tc was based on the fact that
the former virus was highly immunogenic, capable to produce
high titers of neutralizing antibodies to YF virus and a strong IFN-
c cellular response to Yellow Fever Virus and the T. cruzi
TEWETGQI epitope in vaccinated mice. Also, the two viruses
carry in their genomic sequences the CD8+ T cell epitope
TEWETGQI, previously described as a protective immunogen.
Our results indicated that Formulation 1 (composed of 50% of
each virus) was capable to protect nearly 60% of challenged A/J
mice by day 60 post-challenge with reduced parasitemia levels
after trypomastigote challenge in comparison to the immunization
with YF17D/ENS1/Tc or YF17D/NS2B3/Tc recombinant
viruses alone. It has been proposed that a more effective CD8+
T cell recall responses to control re-invading pathogens depend on
the amplitude of the previous CD8+ T cell burst in the primary
infection, because it can generate a higher number of memory T
cells. We demonstrated that Formulation 1 induced a significantly
higher number of IFN-c producing-T cells specific to TE-
WETGQI after only one dose in A/J mice. Although the immune
correlates of protection are still undefined, these findings suggest
that an early T cell activation might correlate with an improved
protective immune response. Further analysis of TEWETGQI-
specific effector and memory CD8+ T cell phenotypes elicited by
Formulation 1 after the first dose should be carried out in order to
confirm this correlation.
We also noted that the recombinant viruses and Formulation 1
were similarly capable to improve the number of IFN-c pro-
ducing-T cells specific to YF peptides or TEWETGQI epitope
after a second dose and induce a significant anamnestic response
to TEWETGQI after a T. cruzi challenge. In this sense, our results
suggest that the early T cell response detected after a single dose of
Formulation 1 might better correlate with the immune protection
levels observed whereas T cell expansion of all viruses groups
detected 15 days after challenge seem to be associated with the
initial resistance of mice to succumb after a lethal T. cruzi infection
instead of a long lasting protection. Notwithstanding the fact that
both YF17D/ENS1/Tc virus and Formulation 1 could control the
parasitemia in the acute phase of T. cruzi infection, only
Formulation 1 provided a superior, although partial, protection
of mice.
Some of the possible explanations for the improved level of
immunogenicity induced by Formulation 1 may be that the
TEWETGQI epitope, being presented by both viruses through
different cell compartments: cytoplasm (released by NS2B/NS3
protease cleavage processing) or ER lumen (mediated by
anchoring of the C-terminus of Den 4 E protein domains) is able
to induce distinct pathways of presentation in vivo, enhancing the
immune response. Another relevant matter is that YF17D/ENS1/
Tc harbors parasite-derived epitopes other than TEWETGQI. As
previously suggested, it is possible that the presence of CD4+ T cell
epitopes in ASP-2 fragments may impact on the priming of
protective CD8+ T cells. In this sense, we speculate that other
epitopes as yet unidentified in the ASP-2261–380 fragment
expressed by the YF17D/ENS1/Tc virus may also have helped
the induction of protective TEWETGQI-specific CD8+ T cells.
It is well-known that accumulation of incorrectly folded proteins
inside the ER is a source of cellular stress, leading to apoptosis. A
plausible explanation of how the YF17D/ENS1/Tc virus presents
ASP-2 epitopes via MHC class II to CD4+ T target cells is that
dendritic cells (DC) engulf the apoptotic bodies that are produced
in cellular stress and may present antigens to CD4+ T cells. The
cross-presentation of ASP-2 epitopes via MHC class I to CD8+ T
cells by APCs that have phagocited apoptotic bodies or by ER-
associated degradation mechanism might also contribute to
improve the CD8 T cell response. In face of these possible
mechanisms, we propose that the CD8+ TEWETGQI epitope
presentation by the YF17D/ENS1/Tc virus is being complemen-
ted by the direct cytosol MHC class I-restricted presentation of
TEWETGQI by the YF17D/NS2B3/Tc virus in YF 17D
Formulation 1 immunizations, resulting in a stronger T CD8+
response.
Nevertheless, we verified that YF 17D viral formulation 1 did
not induce high titers of neutralizing antibodies against YF.
However, Formulation 1 immunization was capable to induce T
cell immune response directed to YF peptides, as observed in
ELISPOT assays, in similar levels to the animal groups that
received the YF 17DD virus vaccine. These results demonstrated
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that the production of neutralizing antibodies to the YF virus may
not always correlate with the generation of CD8+ T cell response.
This observation may be due to the fact that antibody production
is directly dependent on the binding of the antigen to the B cell
receptor, being therefore, also dependent on virus spreading
in vivo.
This preliminary result is in accordance with previous studies in
which YF17D recombinant viruses were shown to elicit a potent
T-cell response. However, the polyfunctionality of these YF 17D
recombinant virus induced cells should be studied by analysing
their cytokine synthesis profiles as well as the functional
capabilities of effector and memory T cell responses, since these
parameters can be associated to mechanisms of defense against
pathogens.
We have studied both arms of the immune response that is,
humoral (neutralizing antibody levels) and cellular (production of
IFN gamma) and both revealed aspects characteristic of YF 17D
vaccine and YF 17D recombinant viruses. We anticipate
extending such evaluation by performing a series of phenotypic
analyses of T CD8+ lymphocyte markers such as T-cell de-
granulation and cytotoxicity CD107a marker, KLRG-1 activation
marker as well as surface markers that differentiate T effector-
memory and T central memory subpopulations such as CD44,
CD62L and CCR7 on the cellular response and its importance for
protection against challenge. It will also be important to study the
CD4+ Th1 cells since they are particularly important to the
development of acquired immunity against experimental infection
in mice with protozoan parasites. In addition we intend to study
the immunoglobulin class in the humoral response as the IgG class
is important for viral clearance. The role of antibodies in T. cruzi
infections is not clear but for the immune response to the vector is
of utmost relevance and may be useful to validate the 17D virus
platform.
In this regard, our findings demonstrate that the co-adminis-
tration of recombinant yellow fever viruses that differentially
express heterologous antigens of a same protein can elicit
a superior immune response in a mouse model. Inclusion of other
immunogenic T. cruzi ASP-2 antigens in new optimized platforms
of YF 17D virus and the use of innovative YF 17D viral
formulations may broaden the immunogenicity of YF 17D
recombinant viruses. This should expand the applicability of YF
17D as a potential recombinant virus vector to express other
antigens for Chagas’ disease vaccine development as well as
antigens from other pathogens causing diseases of interest.
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